University Hospitals Leuven, Leuven Cancer Institute, Dept. of General Medical Oncology
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schöffski, Patrick
NCT01524926 / 2011-001988-52: CREATE: Cross-tumoral Phase 2 With Crizotinib

Checkmark Results for inflammatory myofibroblastic tumor [CREATE]
Nov 2018 - Nov 2018: Results for inflammatory myofibroblastic tumor [CREATE]
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
582
Europe
Crizotinib (PF-02341066)
European Organisation for Research and Treatment of Cancer - EORTC, Pfizer
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
12/17
10/22
NCT04855435: Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Recruiting
1
69
Europe
MBS8(1V270)
MonTa Biosciences ApS, Allucent
Advanced Solid Tumor
04/24
04/24
StrateGIST 1, NCT05489237: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Recruiting
1
269
Europe, US, RoW
IDRX-42
IDRx, Inc.
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
04/26
09/26

Download Options